ClinicalTrials.gg
RecruitingNCT07296471OP-MultiOmicsUpdated Dec 22, 2025

Vitamin D Status and Multi-Omics Profiles in Primary Osteoporosis

An observational study in Primary Osteoporosis, sponsored by Dr. Li Chen. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Dr. Li Chen · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.

Planned enrollment
24th of 30
120 · median 1,750
Started
2025
with 10 others
Observational
30 of 87
12 open now
Primary completion
2027-11
later than 31 of 32 live
Registered
79th of 87
by date

Among the 87 studies in Osteoporosis with a site in China, this one is the 24th largest by planned enrollment of the 30 observational ones that give a count, is one of 11 that started in 2025, is one of 30 observational ones, reaches primary completion later than 31 of the 32 other live ones, and was the 79th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Osteoporosis with a site in China, or all of them as a file.
02

Study summary

This observational study aims to explore the relationships between vitamin D status and genomic, proteomic, and metabolomic profiles in patients with primary osteoporosis.

Eligible participants are adults who are newly diagnosed with primary osteoporosis at Yichang Second People's Hospital. Blood samples will be collected at the initial diagnosis to analyze gene expression, protein levels, and metabolic profiles.

Participants will receive standard clinical treatment according to routine care, but no additional research sampling or follow-up will be performed.

The study seeks to identify molecular patterns associated with osteoporosis and improve understanding of patient responses to therapy.

Read the detailed description

This observational study will enroll adults newly diagnosed with primary osteoporosis at Yichang Second People's Hospital.

Blood samples will be collected at the initial diagnosis for multi-omics analysis, including transcriptomics, proteomics, and metabolomics. Clinical data, including bone mineral density, serum calcium, and vitamin D levels, will also be collected.

No additional research sampling or follow-up is planned after the initial visit.

Data analysis will focus on identifying molecular patterns associated with osteoporosis and potential biomarkers related to vitamin D status. All procedures will follow ethical guidelines and standard clinical practice.

03

Conditions studied

  • Primary Osteoporosis

Browse trials for

Keywords

  • Primary Osteoporosis
  • Vitamin D
  • Multi-omics
  • Transcriptomics
  • Proteomics
  • Metabolomics
  • Biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be recruited from the outpatient and inpatient population of Yichang Second People's Hospital, including adults newly diagnosed with primary osteoporosis as well as healthy adult volunteers. Blood and serum samples will be collected at the hospital laboratory for multi-omics analyses.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy controls: Adults aged ≥18 years, with normal bone mineral density (BMD) confirmed by dual-energy X-ray absorptiometry (DXA), without a history of bone metabolic diseases, major organ dysfunction, or chronic inflammatory/ diseases.
  2. Osteoporotic patients: Adults aged ≥18 years, newly diagnosed with primary osteoporosis according to clinical criteria (T-score ≤ -2.5 SD by DXA), without serious complications that may affect study results.
  3. Participants willing and able to provide written and cooperate with study procedures, including blood and serum sample collection and clinical data recording.

Exclusion criteria

Exclusion Criteria:

  1. Patients with secondary osteoporosis, including but not limited to osteoporosis caused by hyperparathyroidism, tumors, chronic kidney disease, liver cirrhosis, rheumatoid arthritis, or other diseases.
  2. Individuals who have taken vitamin D supplements, anti-osteoporotic drugs, , or other medications affecting vitamin D or bone metabolism within 3 months prior to enrollment.
  3. Pregnant or lactating women, or individuals with mental disorders preventing cooperation with study procedures.
  4. Individuals with acute infections, malignant tumors, or severe liver, kidney, cardiovascular, or cerebrovascular diseases that may affect study outcomes.
  5. Participants with a history of blood transfusion within 1 month prior to enrollment or those unable to provide peripheral blood samples as required.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
120 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Primary Osteoporosis Patients

    Adults newly diagnosed with primary osteoporosis (n=90) at Yichang Second People's Hospital. Blood and serum samples will be collected at the initial visit for transcriptomic, proteomic, and metabolomic analyses. No additional research sampling or follow-up will be performed.

  • Healthy Controls

    Healthy adults without osteoporosis (n=30) at Yichang Second People's Hospital. Blood and serum samples will be collected at the initial visit for transcriptomic, proteomic, and metabolomic analyses. No additional research sampling or follow-up will be performed.

06

What researchers measure

Primary outcomes

  1. Gene Expression Profiles Derived From Transcriptomic Analysis

    Quantitative gene expression levels obtained from whole blood RNA sequencing, including the identification of differentially expressed genes and their expression magnitudes (e.g., log2 fold change, normalized counts).

    Time frame: Baseline

  2. Serum Protein Abundance Profiles From Proteomic Analysis

    Quantitative abundance of serum proteins measured through mass spectrometry-based proteomics, including identification of differentially expressed proteins and their relative abundance levels.

    Time frame: Baseline

  3. Serum Metabolite Abundance Profiles From Metabolomics Analysis

    Quantitative serum metabolite abundance determined by untargeted metabolomics, including identification of metabolites with altered abundance and their relative intensity values.

    Time frame: Baseline

Secondary outcomes

  1. Bone Mineral Density (BMD)

    Bone mineral density measured at the lumbar spine and/or hip using dual-energy X-ray absorptiometry (DXA).

    Time frame: Baseline

  2. Serum 25-Hydroxyvitamin D Level

    Serum concentration of 25-hydroxyvitamin D (25(OH)D) assessed at enrollment to evaluate vitamin D status.

    Time frame: Baseline

  3. Serum Calcium Level

    Serum calcium concentration measured at enrollment as a routine biochemical indicator of bone metabolism.

    Time frame: Baseline

  4. Serum Phosphate Level

    Serum phosphate concentration measured at enrollment to assess mineral metabolism status.

    Time frame: Baseline

  5. Serum Magnesium Level

    Serum magnesium concentration measured at enrollment as part of biochemical evaluation related to bone health.

    Time frame: Baseline

  6. Serum Osteocalcin Level

    Serum osteocalcin concentration measured as a marker of bone formation.

    Time frame: Baseline

  7. Serum Alkaline Phosphatase (ALP)

    Serum alkaline phosphatase level assessed as an indicator of bone turnover and metabolic activity.

    Time frame: Baseline

  8. Serum β-CTX Level

    Serum C-terminal telopeptide of type I collagen (β-CTX) measured to evaluate bone resorption activity.

    Time frame: Baseline

  9. Serum P1NP Level

    Serum procollagen type 1 N-terminal propeptide (P1NP) measured as an additional bone formation marker.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data including multi-omics datasets (transcriptomic, proteomic, metabolomic) and clinical measurements will be shared with qualified researchers upon reasonable request.

Supporting information: Study protocol

Time frame: De-identified individual participant data and supporting information will be available to qualified researchers starting after publication of the primary study results and will remain available for at least 5 years.

Access criteria: De-identified individual participant data and supporting information will be accessible to qualified researchers who submit a reasonable proposal and agree to a data use agreement. Data will be shared electronically after approval of the request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Dec 22, 2025
StartActual
Nov 11, 2025
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07296471
Lead sponsor
Dr. Li Chen
Responsible party
Dr. Li Chen (Associate Chief Physician, Department of Laboratory Medicine, Yichang Second People's Hospital, Yichang Second People's Hospital) — Sponsor-investigator
First posted
Dec 22, 2025
Start date
Nov 11, 2025
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Dec 22, 2025

Study contacts

Li Chen, MD
Contact
chenli18995889811@163.com
+86-717-6741005

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion